LFTs: an update A MacGilchrist PLIG meeting 31st January 2019
|
|
- Bathsheba McCormick
- 5 years ago
- Views:
Transcription
1 LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019
2 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant liver disease The case for investigation above data based on short term follow up (3 years) liver disease is second common cause of death under 65 yrs presents at advanced stage with high mortality
3 LFTs: what are we trying to achieve? (2) Diagnosis ALD NAFLD Chronic viral hepatitis Hepatitis B Hepatitis C Haemochromatosis Autoimmune liver disease PBC AIH Biliary disease Cancer Severity liver function bilirubin albumin INR fibrosis/cirrhosis 1 0 care: indirect ratios e.g. Fib4 (2 0 care: Fibroscan, hyaluronic acid)
4 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
5 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
6 Changes 1: Refer to Hepatology (rather than GI) all are directed to liver unit, RIE all undergo daily etriage use SCI gateway both for traditional clinic referral and as electronic helpline 40% of hepatology referrals do not result in liver appointment no waiting list for liver clinic
7 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
8 Changes 2: include transferrin saturation when measuring ferritin raised ferritin very common, only minority have iron overload, other explanations include alcohol XS ALD NAFLD inflammation BUT haemochromatosis is common, underdiagnosed and readily treated, so.. if raised ferritin ( > 300 ug/l) and TS (>50%), check HFE (haemochromatosis gene test)
9 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
10 Changes 3: restrict liver immunology screen + ANA < 1/80 common in normal population only request liver immunology screen if elevated ALT or ALP (i.e. not if isolated GGT) include immunoglobulins as well as liver autoantibodies (ANA, ASMA and AMA) in liver immunology screen ignore ANA < 1/80 if other AAs negative and IgG normal
11 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
12 Changes 4: stage fibrosis using FIB-4 rather than AST:ALT ratio indirect ratios AST: ALT ratio FIB-4 age, AST, ALT, platelets automated validated for NAFLD and Hepatitis C Others APRI (AST, platelets) NFS (age, BMI, AST, ALT, platelets, albumin, diabetes) AST > ALT: either fibrosis or ALD direct markers imaging: fibroscan, ARFI biomarkers: hyaluronic acid, ELF
13 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
14 Changes 5: to GGT or not to GGT? pre 2012: LFTs include GGT if RIE lab (1 0 and 2 0 care) LFTs do not include GGT if WGH lab (1 0 and 2 0 care) 2012-present: LFTs include GGT if 1 0 care LFTs do not include GGT if 2 0 care future (maybe!): LFTs will not include GGT in 1 0 care or 2 0 care BUT request GGT if diagnosing/assessing/investigating isolated raised ALP NAFLD T2DM (will be included in order data set) alcohol misuse cirrhosis Audit of LFTs in primary care in Edinburgh in one month raised GGT 4,999 raised GGT alone 3,238 GGT > % (349) had an USS of these 71% (248/349) abnormal 10.6% (37) cirrhosis
15 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
16 Changes 6: perform liver screen after single raised LFTs cost effective but apply common sense applies only to investigation of asymptomatic abnormal LFTs Changes 7: lower threshold for abnormal ALT What is an abnormal ALT? (currently > 50) men > 30 women > 19
17 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016
18 Changes 8: 1 0 care follow-up
19 ilfts 1
20 Tayside pilot in 6 GP practices: when GP request LFTs, asked if wants liver screen? If yes, adds BMI and alcohol history to request form auto analyser selects additional tests according to results uses algorithms to advise GP of outcome: 1. likely ALD without significant fibrosis 2. likely NALFD without significant fibrosis 3. likely ALD or NAFLD with significant fibrosis 4. possible other diagnosis (with or without fibrosis) 5. unclear 1 & 2 manage in primary care 3 & 4 refer to hepatology 5 GP review (?) ilfts 2 ilfts 3 Tayside pilot completed, role out in progress, limited uptake Pilots elsewhere delayed by technical problems SG and HBs remain interested, National lead appointed, planned further pilot in GGC Watch this space, but don t hold your breath!
21 LFTs: what are we trying to achieve? (3) explanation for abnormal LFTs? or opportunistic screening for liver disease? but are LFTs a good way to detect liver disease? is a better starting point the at risk population? overweight diabetic XS alcohol is a better screening tool a fibrosis marker e.g. Fibroscan n = 79 26% abnormal Fibroscan 16% significant liver disease 8% cirrhosis
22 Offered Fibroscan to patients with XS alcohol and T2DM in selected GP practices in Nottingham
23 summary now continue to use RefHelp pathway to investigate LFTs. 2. include TS with ferritin 3. measure liver AAs and IgGs only if raised ALT or ALP 4. use SCI gateway referrals as liver helpline soon probable removal of GGT from initial LFTs 2. apply pathway to any asymptomatic LFTs 3. FIB-4 rather than AST:ALT ratio to assess liver fibrosis in the future ilfts 2. Fibroscan to screen for liver disease in at risk patients always... think why you are requesting LFTs!
2. Liver blood tests and what they mean p2 Acute and chronic liver screen
Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More informationInvestigating and Referring Incidental Findings of Abnormal Liver Tests
Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common
More informationAnaemia Pathway. Anaemia. Type of Anaemia Check Haematinics (Iron stores,b12,folate) Fit for endoscopies. endoscopies yes no. Non Iron Deficient
Cognitive if unable to consent, must attend clinic with next of kin to act as advocate. Rockwood Frailty Score 6 consider appropriate referral to elderly care. See attachment Anaemia Pathway Anaemia Type
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More informationWhat to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon
What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon "it looks like there's something wrong.with your television set. Matt Groenig, creator of The Simpsons Probability of an abnormal screening
More informationLiver Network. Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities
Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Dr Mark Hudson Dr Stuart McPherson On behalf of the North East & North Cumbria Hepatology Network 1
More informationAbnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital
Abnormal LFTs in migrant populations Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital www.migrationobservatory.ox.ac.uk Migrants in London Migrants in London Migrants in London Common liver
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationA Rational Evidence-based Approach to Abnormal Liver Tests
A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course Radisson Blu Hotel, Cebu City misnomer Liver Function Tests Does
More informationManaging abnormal LFTs in Primary care
Managing abnormal LFTs in Primary care Summary guideline, April 2015 Sally Hull, Lucy Carter Managing abnormal LFTs in Primary care Draft guideline written by Dr Sally Hull and Dr Lucy Carter at CEG, with
More informationLiver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities
Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Dr Mark Hudson Dr Stuart McPherson On behalf of the North East & North Cumbria Hepatology Network 1
More informationNHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.
Advice Statement 010-18 July 2018 Advice Statement What is the most accurate and cost-effective direct test (ELF test, hyaluronic acid, P3NP, Fibroscan or ARFI elastography) for detecting and staging liver
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationChewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018
Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Faculty/Presenter Disclosure Faculty: Michael Kolber Relationships with financial sponsors: Grants/Research Support: Alberta College of
More informationInitial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
More informationWestern Health Specialist Clinics Access & Referral Guidelines
Gastroenterology Specialist Clinics at Western Health: Western Health provides the following Specialist Clinics for patients who require assessment and management of Gastroenterology / Hepatology conditions.
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More information9/28/2016. Elevated Liver Function Tests: A Case Based Approach. Objectives. Identify patterns of abnormal liver function tests
Elevated Liver Function Tests: A Case Based Approach Terrance M. James, NP C The Oregon Clinic Hepatology 503 963 2707 tejames@orclinic.com Objectives Identify patterns of abnormal liver function tests
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationHereditary Haemochromatosis For GPs
Hereditary Haemochromatosis For GPs What is Hereditary Haemochromatosis? Hereditary Haemochromatosis () is a common autosomal recessive disease resulting in excessive absorption of dietary iron from the
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationCITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS
CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS Interpreting abnormal liver function tests (LFTs) and trying to diagnose any underlying liver disease is a common scenario in Primary
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationIn response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network
Evidence Note Number 82 July 2018 In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network What is the most accurate and cost-effective direct test (ELF test, hyaluronic
More informationCase #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis
45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationMrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014
Pre-Conference Nurse s Course in partnership with Mrs Janet Catt Royal Free London NHS Foundation Trust Janet Catt MSc RN Lead Nurse Specialist Practic 1 Liver blood tests monitoring cirrhosis HIV/HCV
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationMaking the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham
Making the best use of liver biopsy: clinical perspective Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham Trepanning most efficacious for the relief of maladies so diverse and troublesome
More informationAbnormal LFTs and NAFLD. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal LFTs and NAFLD Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationChronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh
Chronic Hepatitis Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh Autoimmune Hepatitis Annual incidence 1.9/100 000 in N Europe Prevalence 16.9/100 000 ~5% all liver transplants Female preponderance
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More informationHereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee
Hereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee Hereditary Haemochromatosis A disorder of iron metabolism Inherited disorder Iron Essential micro-nutrient Toxicity when
More informationAbnormal LFTs GP CME 2014 Workshop Fri 55 mins. Dr Alasdair Patrick Macmurray Center GP CME 2014
Abnormal LFTs GP CME 2014 Workshop Fri 55 mins Dr Alasdair Patrick Macmurray Center GP CME 2014 Dr Alasdair Patrick Gastroenterologist Overview Liver Function Tests Cholestasis Hepatocellular / Hepatitic
More informationPretreatment Evaluation
Pretreatment Evaluation Objective At the end of this lecture, the learner will be able to: Outline the appropriate evaluation of a person infected with HCV in order to assess the benefits and risks of
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Scott W. Biggins, MD, MAS Assistant Professor Division of Gastroenterology UCSF Scott.Biggins@ucsf.edu (Thanks to Hal Yee, MD) This Morning s Presentation Clinical vignettes
More informationMr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK
Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK Ms Sally Bufton University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham Mrs Janet Catt Royal Free
More informationPhysical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford
Physical Aspects of Substance Misuse in Older People Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford Areas to cover Hepatitis C Curable disease New drugs (goodbye interferon) Drug Interactions
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationBiochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya
Biochemical Investigations in Liver Disease Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical markers Albumin ALP ALT, AST Gamma-glutamyl transpeptidase
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationNon Alcohol Fatty Liver Disease (NAFLD) An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Non Alcohol Fatty Liver Disease (NAFLD) An information guide Non Alcohol Fatty Liver Disease (NAFLD) What is Non Alcohol Fatty Liver Disease?
More informationAcute Hepatitis: An Approach to Infectious and Other Causes. Mary Anne Cooper MSc, MD, MEd, FRCPC
: An Approach to Infectious and Other Causes Mary Anne Cooper MSc, MD, MEd, FRCPC Faculty: Dr. Mary Anne Cooper Relationships with commercial interests: Consulting Fees: Lupin Pharmaceuticals, Canada Objectives
More informationLiver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
More informationApproach to the Patient with Liver Disease
Approach to the Patient with Liver Disease Diagnosis of liver disease Careful history taking Physical examination Laboratory tests Radiologic examination and imaging studies Liver biopsy Liver diseases
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationNon-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology
Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease
More informationGI DISEASE WORKSHOP CASE STUDIES
GI DISEASE WORKSHOP CASE STUDIES American Academy of Insurance Medicine Triennial Course in Insurance Medicine 2012 Clifton Titcomb Jr., MD (Hannover Re) James Topic, MD (Protective Life) 1 CASE #1 Application
More informationWestern Health Specialist Clinics Access & Referral Guidelines
Haematology Specialist Clinics at Western Health: Western Health runs MBS funded Specialist Clinics on a Wednesday and Thursday afternoon at its Sunshine Hospital site for patients who require assessment
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationMay 2015 CLINICAL REFERENCE. gastroenterology
May 2015 CLINICAL REFERENCE gastroenterology Introduction As co-leads for the Alberta Referral Pathway for Gastroenterology (GI) and on behalf of our fellow working group, we are pleased to present this
More informationDiseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:
Diseases of liver Dr. Mohamed. A. Mahdi Mob: 0123002800 4/2/2019 Cirrhosis Cirrhosis is a complication of many liver disease. Permanent scarring of the liver. A late-stage liver disease. The inflammation
More informationPrototypes of autoimmune hepatitis and sclerosing cholangitis in childhood
RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationLaboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland
Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationHEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM
EVALUATION OF LIVER FUNCTION R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM METABOLIC FUNCTION
More informationManagement of acute alcoholic hepatitis
Management of acute alcoholic hepatitis Yesim ALAHDAB Marmara University Hospital, Istanbul/TURKEY 5 th European Young Hepatologists Workshop August, 27-29, 2015 Moulin de Vernègues, France 1.4L ALCOHOL
More informationWEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry
MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationCHAPTER 1. Alcoholic Liver Disease
CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end
More information4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS
APPROACH TO THE PATIENT WITH ABNORMAL TESTS Kimberly A. Brown, M.D, FAST, FAASLD, AGAF Chief, Division of Gastroenterology and Hepatology Henry Ford Hospital Henry Ford Health System Detroit, Michigan
More informationChronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths
Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationNon-alcoholic fatty liver disease
Non-alcoholic fatty liver disease Link to this article online for CPD/CME credits Naveed Sattar, 1 Ewan Forrest, 2 David Preiss 1 1 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationAssessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY
Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis
More informationLiver Disease. Is it a big problem? Who is affected What causes it What is required. Community Hepatology Practical tips. Change of Tempo & Style
Liver Disease Is it a big problem? Who is affected What causes it What is required Change of Tempo & Style Community Hepatology Practical tips Transplants ~700 HCC ~3000 Liver Failure ~5000 Deaths ~12000
More informationObjectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018
10/15/2018 Objectives Hepatitis C Screening, Treatment and the Family Physician Wayne Ghesquiere MD FRCPC Infectious Diseases & Internal Medicine Division of Infectious Diseases Victoria, BC At the end
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationDr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1
Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1 No disclosures. 15/09/2018 2 Sub-Saharan Africa (SSA) has a high burden of morbidity and mortality resulting
More informationTest Profiles Time for a Change. Tony Badrick (AACB Harmonisation Committee)
Test Profiles Time for a Change Tony Badrick (AACB Harmonisation Committee) 1. Why Profiles 2. Profiles A. LFT B. Electrolyte C. Renal D. Bone 3. Summary Same clothes!! Harmonisation! Same car!! Harmonisation!
More informationDiagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationBHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over
BHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over Data collection for BHIVA s 2018 national clinical audit is now open until 15 June. The aim is to assess adherence to standards
More informationGeneral Guidelines for Health professionals
General Guidelines for Health professionals Page 1 Haemochromatosis Introduction Hereditary haemochromatosis (HH) now easily screened for as most symptomatic individuals are homozygous for the C282Y mutation
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More information